title: [Rate of cervical intraepithelial neoplasia before HPV vaccination, Alpes-Maritimes 2006].
abstract: OBJECTIVE
  The incidence rate of uterix cervical cancer in 2006 in the Alpes-Maritime was 6.2 per 100,000 women. The existence of curable precancerous lesions and an effective vaccine make it a target cancer in public health. The objective of this study was to establish prevalence of cervical intraepithelial neoplasia in 2006 before the campaign of vaccination against HPV.
  
  
  METHODS
  Retrospective study including all histological samples (smears excluded) of the cervix, performed in 2006 with a diagnosis of intraepithelial Neoplasia among residents of the Alpes-Maritimes. Extraction codes' corresponding was carried out by all pathology laboratories located in the Alpes-Maritimes and around. A comparison of codes with pathology reports was performed for 11.4% of random samples.
  
  
  RESULTS
  This study included 2066 patients aged 16 to 88 years. The average age was 37.3 years (±12.3). Among these patients, most pejorative intraepithelial neoplasia lesion was CIN 1, CIN 2, CIN 3, respectively for 941, 380 and 375 patients. Prevalence of CIN 2 among women 20 to 25 years old was similar to rates seen in 35 to 39 years old (166.5 per 100,000) and the rate of CIN 3 was similar to that seen in 45 to 49 years (78.1 per 100,000).
  
  
  CONCLUSIONS
  Rates of CIN for the entire female population of the Alpes-Maritimes in 2006 has been established. The results observed in women aged less than 25 years old will be useful for comparison after the campaign of vaccination against HPV.
authors.affiliation: Département de santé publique, hôpital Archet-1, CHU de Nice, niveau 1, route Saint-Antoine-de-Ginestière, Nice cedex, France. bailly.l@chu-nice.fr
authors.forename: L
authors.initials: L
authors.lastname: Bailly
authors.forename: A
authors.initials: A
authors.lastname: Bongain
authors.forename: E
authors.initials: E
authors.lastname: Mariné Barjoan
authors.forename: C
authors.initials: C
authors.lastname: Sattonnet
authors.forename: J
authors.initials: J
authors.lastname: Saos
authors.forename: M-L
authors.initials: ML
authors.lastname: Durant
authors.forename: F
authors.initials: F
authors.lastname: Mousteou
authors.forename: C
authors.initials: C
authors.lastname: Pradier
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines